Anosognosia for Levododopa-induced Dyskinesias in PD – Frequency
Objective: To evaluate the factors and possible mechanisms associated with anosognosia for LIDs in patients with PD using movie presentations and mirrored self-images. Background: Levodopa-induced…The Personal Kinetigraph Fluctuator Score Identifies Motor Fluctuations in Parkinson’s disease
Objective: To evaluate the Personal Kinetigraph (PKG) fluctuator score (FS) in detecting motor fluctuations in Parkinson's disease (PD) patients. Background: Fluctuations of response to levodopa,…The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
Objective: To investigate the effect of metabotropic glutamate receptor 2 (mGluR2) activation on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset…Design and personalisation of new upper-limb dynamic orthoses for dystonia and dyskinesia
Objective: The study proposes a method to obtain anatomically- and functionally-personalised orthotics for the dynamic postural control of the upper limb. Background: The orthotic treatment…Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.
Objective: To investigate if there is a significant relationship between weight loss in persons with Parkinson’s disease and side-effect incidence, and if so to what…Automated Telehealth Diagnostics for Remote Parkinson Monitoring
Objective: To clinically assess and evaluate the impact of automated telehealth diagnostics on patients with Parkinson's disease (PD). Background: A single evaluation in a clinical…Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece
Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality…FBOX07 mutation with juvenile parkinsonism and behavioral disorders
Objective: FBX07 (PARK15) mutations cause juvenile parkinsonism with autosomal ressesive inheritance. Juvenile parkinsonism, pyramidal tract signs and atypical symptoms such as dystonia, chorea, behavioral disturbances,…Self-perception of daily performance in relation to motor performance in advanced Parkinson’s disease – Case studies
Objective: To evaluate Parkinson's disease (PD) patients' perception of their performance of daily living (ADL) in their “ON” and “OF” stages and relate them to…Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease
Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…
- « Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 44
- Next Page »